BCL-6 and other genomic alterations in non-Hodgkin’s lymphoma (NHL)

M Butler1, N Corbally1, PA Dervan1,2 and DN Carney1

1Department of Medical Oncology and Pathology, Mater Misericordiae Hospital, Eccles Street, Dublin 7; 2Department of Pathology, Biotechnology Centre, University College, Dublin, Ireland

Summary This study reports on the frequency and disease association pattern of a number of gene rearrangements in a large panel of lymphoid tumours (n = 94). We detected the t(11;14) translocation, involving rearrangement of the BCL-1 locus, in 60% of mantle cell lymphomas. The BCL-2 gene, located at band 18q21, was rearranged in 42% of follicle centre lymphomas (FCL) and in 15% of diffuse large B-cell (DLBCL) lymphomas. In this study, 80% of the c-MYC rearrangements were detected in aggressive diffuse lymphoma subsets but, interestingly, 9% of FCL showed involvement of (8q24) translocation. In our study, rearrangements of the BCL-6 gene at band 3q27 were found in 31% of DLBCL lymphomas. Interestingly, 50% of the BCL-6 rearrangement positive lymphoma cases had coexisting gene rearrangements involving all of the aforementioned gene loci. The molecular dissection of these genes will improve our understanding of the genesis of the diverse clinicopathological subtypes.

Keywords: lymphoma; BCL-6; gene rearrangements

Non-Hodgkin’s lymphomas (NHL) arise from the clonal expansion of B (approximately 85%) and T lymphocytes (15%) that have transformed as a result of DNA damage at various points in lineage differentiation. They represent a heterogeneous group of neoplasms that vary in their clinical presentation, response to treatment and disease outcome. This clinicopathological diversity may be mediated by the deregulation of different proto-oncogenes together with the inactivation of different tumour-suppressor genes. Previous studies have indicated correlations between specific chromosomal abnormalities and defined subtypes of NHL (Koduru et al, 1987; Cotter, 1990). The most frequently observed genetic abnormalities in NHL are reciprocal translocations. In B-cell NHL, these events often result in the juxtaposition of proto-oncogenes with the immunoglobulin genes (14q32, 22q11 and 2p12) leading to transcriptional deregulation of the proto-oncogenes. If these genes participate in the fine control mechanisms regulating normal lymphocyte development, then their disruption may help promote lymphomagenesis.

Recurring translocations in NHL include the t(14;18)(q32;q21) detected in 50–70% of FCL in Europe (Dejong et al, 1989; Clark et al, 1992; Lambrechts et al, 1992), the t(8;14)(q24;q32) detectable in most Burkitt’s lymphomas (Lenoir et al, 1982) and the t(11;14)(q13;q32) detectable in 50–60% of mantle cell lymphomas (MCL) (Raffeld and Jaffe, 1991; DeBoer et al, 1993). The emergence of new techniques such as DNA fibre fluorescent in situ hybridization (FISH) has increased the detection of 11q13 breakpoints to approximately 95% in MCLs (Vaandrager et al, 1996). These translocations ‘trigger’ the oncogenic conversion of the anti-apoptosis gene BCL-2 (Bakhshi et al, 1985; Cleary and Sklar, 1985; Tsujimoto et al, 1985), the proto-oncogene encoding transcription factor c-MYC (Dalla-Favera et al, 1982; Taub et al, 1982) and the cell cycle regulation gene BCL-1 (CCND1/PRADI) (Arnold et al, 1989; Raffeld and Jaffe, 1991; Williams et al, 1991; Komatsu et al, 1994), respectively, by deregulating their expression. The putative oncogene deregulated by the t(11;14)(q13;q32) was identified by two groups of investigators and is located approximately 120 kb telomeric from the major translocation cluster (MTC) breakpoint region. The gene was originally named PRADI because of its original recognition in parathyroid adenomas (Arnold et al, 1989) but has now been officially named CCND1. The gene encodes for cyclin D1 and is overexpressed in nearly all cases of MCLs.

Recently, a translocation involving the 3q27 region with numerous partner chromosomes (1q21, 2q21, 4p11, 4q27, 5q13, 6q23, 6q25, 6p21, 7p12, 8q24, 11q13, 12p11, 12p12, 14q24, 15q21, 16p13, 14q32, 2p12, 22q11) has been described in approximately 30% of diffuse lymphomas with a large-cell component (Bastard et al, 1994; LoCoco et al, 1994). Several groups of investigators identified the gene involved in 3q27 translocations and named it BCL-6 or LAZ-3 and BCL-5 (Kerckhaert et al, 1993; Ye et al, 1993a; Miki et al, 1994). Translocations at 3q27 involving BCL-6 display atypical properties when compared with the previously characterized lymphoma-associated translocations: (1) the partner chromosomes are not limited to the Ig gene loci; (2) the coding region of BCL-6 remains on derivative 3 following all translocations described to date; and (3) the breakpoints of common (14q32) and variant (2p12, 22q11) translocations both cluster in the 5' region of the gene. This is in contrast to BCL-1, BCL-2 and c-MYC rearrangements in which the breakpoints of the Ig heavy-chain (14q32) and light-chain (22q11 and 2p12) genes locate at opposite sides of the target genes (Croce et al, 1985; Osada et al, 1989; Komatsu et al, 1994). Interestingly, the reciprocal partner chromosomes of 3q27 may mark the sites of known as well as yet to be identified gene loci.

Received 9 August 1995
Revised 8 July 1996
Accepted 4 December 1996

Correspondence to: M Butler, Lab. 15-410, College of Physicians & Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA

© 1997 Cancer Research Campaign

British Journal of Cancer (1997) 76(11), 1641–1645
BCL-6 rearrangements have been suggested to be relatively specific for large-cell lymphomas that occur de novo (i.e. without a preceding follicular pathogenesis) and also to define a BCL-2-independent pathway of lymphomagenesis (LoCoco et al, 1994). However, several groups of investigators have published findings of BCL-6 rearrangements in both follicular lymphomas as well as DLBCL lymphomas carrying (t14;18) that oppose the possibility of these two events being exclusive of one another (Ohno et al, 1994; Otsuki et al., 1995). The BCL-6 gene encodes for a zinc finger protein which shares homologies with several transcription factors that participate in the control of cell proliferation, differentiation and organ formation (Bastard et al, 1992; Baron et al, 1993; Kerckaert et al, 1993; Ye et al, 1993b).

The objectives of this study were to determine (1) the frequency and (2) the disease specificity of BCL-1, BCL-2, c-MYC and BCL-6 gene rearrangements in a large series of lymphoid malignancies representative of the Irish population. Also, we discuss interesting findings of several coexisting rearrangements in lymphoid malignancies, with particular emphasis on those associated with the BCL-6 gene.

MATERIALS AND METHODS

Patient materials

Fresh-frozen lymph node biopsy specimens were obtained from 94 non-Hodgkin’s lymphoma (NHL) patients who attended the Mater Misericordiae Hospital between January 1987 and March 1994. The tumours were classified histologically according to the Revised European–American Lymphoma (REAL) Classification (Harris et al, 1994).

DNA extraction and Southern blot analysis

High molecular weight DNA was obtained by the standard sodium dodecyl sulphate (SDS)/proteinase K and phenol chloroform extraction method (Sambrook et al, 1989). For Southern blot analysis, 10 µg of DNA was digested with the appropriate restriction endonuclease, electrophoresed on a 0.8% agarose gel, de-natured, neutralized and transferred to nylon membranes (Hybond N+, Amersham). Filters were then hybridized with probes that had been radiolabelled using a random primer DNA labelling kit (Promega, Madison, WI, USA) with [α-32P]dCTP. After hybridization, membranes were washed with 2 × standard saline citrate (SSC) and 0.1% SDS at 65°C for 40 min followed by 0.2×SSC and 0.1% SDS at 65°C for 50 min. The membranes were then exposed with intensifying screens at −70°C for 2–7 days.

DNA probes

The organization of the BCL-1 locus was investigated by hybridization of BamHI, EcoRI and HindIII digested DNA with a 2.1-kb SsrI fragment of the major translocation cluster (MTC) breakpoint region of the BCL-1 gene (gift from Dr Y Tsujimoto, Wistar, Philadelphia, PA, USA). The configuration of the BCL-2 gene was assessed by hybridization of EcoRI, HindIII and PstI digested DNA with a 3.5-kb EcoRI–HindIII fragment cloned from the major breakpoint region (mbR) of the BCL-2 gene (courtesy of Dr Y Tsujimoto). Two different probes were used to assess the configuration of the c-MYC gene; HindIII and EcoRI-digested DNA were probed with the first exon probe, a 1.9-kb ClaI–SsrI fragment and the third exon probe, a 1.5-kb EcoRI–HindIII fragment (both gifts from Dr I Kirsch, National Cancer Institute, Bethesda, MD, USA). Finally, the BCL-6 gene was analysed by hybridization of BamHI and Xbal DNA digests with a 4.0-kb SacI probe (kindly provided by Dr BH Ye, College of Physicians and Surgeons, Columbia University, NY, USA).

RESULTS

Table 1 gives the frequencies of the gene rearrangements BCL-1, BCL-2, c-MYC and BCL-6 in the total cohort of 94 NHL. Representative results of hybridization analysis with the major breakpoint region probe of BCL-6 to tumour DNAs digested with BamHI are presented in Figure 1.

We detected rearrangements of BCL-1 at the MTC breakpoint region in 60% (6 out of 10) of MCLs. In addition, this was detected in a case of small lymphocytic lymphoma (1 out of 5; 20%), as well as in 2 of 33 (6%) diffuse large B-cell (DLBCL) lymphomas.

Table 1 Incidence of gene rearrangements in a panel of non-Hodgkin's lymphoma

| Lymphoma subtype                          | BCL-1 | BCL-2 | c-MYC | BCL-6 |
|-------------------------------------------|-------|-------|-------|-------|
| Precursor B-lymphoblastic                 | 0/1   | 0/1   | 0/1   | 0/1   |
| B-cell lymphocytic leukaemia/lymphocytic lymphoma | 1/5 (20%) | 0/4 | 0/5 | 0/5 |
| Mantle cell lymphoma                      | 6/10 (60%) | 0/6 | 0/8 | 0/6 |
| Follicular centre lymphoma, follicular     |       |       |       |       |
| Grade I                                   | 0/8   | 4/6 (67%) | 0/6 | 0/6 |
| Grade II                                  | 0/8   | 2/3 (25%) | 1/5 (20%) | 0/7 |
| Grade III                                 | 0/3   | 0/3 (67%) | 0/3 | 1/3 (33%) |
| Follicular centre lymphoma, diffuse small cell (provisional) | 0/11 | 3/9 (33%) | 1/8 (13%) | 0/9 |
| Diffuse large B-cell                      | 2/33 (6%) | 4/27 (15%) | 4/28 (14%) | 9/29 (31%) |
| Primary mediastinal large B-cell lymphoma | 0/1   | 0/1   | 0/1   | 0/1   |
| Burkitt's lymphoma                        | 0/1   | 0/1   | 1/1 (100%) | 0/1 |
| High-grade B-cell lymphoma, Burkitt-like (provisional) | 0/4 | 0/4 | 1/4 (25%) | 0/3 |
| Precursor Tlymphoblastic lymphoma         | 0/3   | 0/3 (60%) | 0/3 | 0/2 |
| Peripheral T-cell lymphomas               | 0/5   | 0/4   | 0/5   | 0/4   |
| Overall frequency                         | 9/93 (10%) | 15/77 (19%) | 10/79 (13%) | 10/77 (13%) |

*Classified according to the REAL (Revised European American Lymphoma) classification.
The t(14;18) chromosomal translocation, involving rearrangement of BCL-2, was the most common genetic abnormality encountered in our series of NHLs (19%; 15 out of 77). Bcl-2 was rearranged in 42% (11 out of 26) of follicle centre lymphomas (FCL), in 15% (4 out of 27) of DLBC lymphomas and in no other lymphoma subtypes.

Alterations of the c-MYC locus were observed in 25% (one out of four) of high-grade B-cell lymphomas (Burkitt-like, provisional), 50% (two out of four) of precursor T-lymphoblastic lymphomas, 14% (4 out of 28) of DLBC lymphomas and in the single Burkitt’s lymphoma case (one out of one; 100%). A FCL (grade II) demonstrated rearrangement of c-MYC; this particular patient had a previous FCL (grade I) and the patient died 30 months following diagnosis. We also report a rare finding of a lymphoma case, again of follicle centre cell origin (areas of diffuse histology seen), that demonstrated both c-MYC and BCL-2 rearrangements. This patient died 36 months from diagnosis.

In our study, we report BCL-6 rearrangements in 31% (9 out of 29) of DLBC lymphomas. One out of 25 (4%) FCLs were positive for this rearrangement, which occurred in a FCL of large-cell morphology. Immunophenotypic analysis showed that all tumours displaying this rearrangement were of B-cell phenotype. Five of ten (50%) of these tumours had additional gene rearrangements, involving the BCL-2 gene in three cases, c-MYC and BCL-1 genes in the two remaining cases. One of the DLBC lymphomas showing a co-existing BCL-2 rearrangement had an antecedent history of a FCL (grade I), and the DLBC lymphoma with a co-existing BCL-1 rearrangement had a previously reported low-grade lymphoma (slide not available for review). The patient with both BCL-6 and c-MYC rearrangements (biopsy specimen taken at time of diagnosis) died 7 months later.

**DISCUSSION**

Recurrent translocations and their corresponding molecular counterparts, gene rearrangements, represent important mutational mechanisms that characterize approximately 95% of NHL.

The t(11;14) translocation is detectable in nearly all MCLs by applying novel DNA fibre FISH methodology. This lymphoma subtype corresponds closely to centrocytic (CC) lymphoma in the Kiel classification (Gerard-Marchant et al, 1974), lymphocytic lymphoma of intermediate differentiation (IDL) by Berard et al (1974) and diffuse small cleaved-cell (DSCC) lymphoma in the Working Formulation (WF) (1982). The PRADI/CCND1 gene is now recognized as the once elusive gene involved in the t(11q13) breakpoint, and its expression is up-regulated in cell lines or disorders carrying the t(11;14) translocation (Seto et al, 1992). This gene encodes cyclin D1, which plays an important role in cell cycle regulation and the progression of cells through the G1–S phase (Hunter et al, 1994).

In our study, we detected BCL-1 rearrangements in 60% (6 out of 10) of MCLs, a single case of lymphocytic lymphoma and in 6% (2 out of 33) of DLBC lymphomas. These DLBC lymphomas may actually represent elastic variants of previous MCLs, as this has been reported to occur, albeit at a relatively low frequency. This suggestion is partly substantiated by the knowledge that one of these two cases had a known DSCC lymphoma (WF) which corresponds closely to MCL in the REAL classification scheme (slide not available for review). Our findings of 60% of BCL-1 rearrangements in MCLs correlate with the findings of five groups of investigators who reported 49% (n = 77) of their IDL/CC lymphomas positive for this rearrangement (Medeiros et al, 1990; Williams et al, 1990; Wotherspoon et al, 1990; Athan et al, 1991). The reported 50–60% incidence of this rearrangement may be an underestimate of the true frequency because most investigators analysed only the MTC region of the BCL-1 locus. The advent of FISH technology has given us a powerful tool to detect both clustered as well as scattered breakpoints. This is well illustrated by Vaandregler et al (1996) who applied DNA fibre FISH technology to successfully detect 11q13 breakpoints in 95% (19 out of 20) of their MCLs, while their previous Southern blot data gave a much lower frequency of 53%.

In the t(14;18) translocation, the joining region of the IgH gene (14q32) is juxtaposed to the BCL-2 gene (18q21), which results in the overexpression of a chimeric BCL-2/IgH message (Graninger et al, 1987; Seto et al, 1988). Hockenberry et al (1990) showed that the BCL-2 protein is able to block programmed cell death.

In our series, BCL-2 rearrangement was the most frequent genetic abnormality occurring at 19%. Among the various subtypes, we detected BCL-2 rearrangements in 42% of FCL and in 15% of diffuse lymphomas, suggesting its association mainly with tumours of follicular histology. Previous investigators reported BCL-2 rearrangements in 55–70% of follicular lymphomas (Lambrechts et al, 1987; deJong et al, 1989; Clark et al, 1992) and in 10–30% of diffuse lymphomas. However, the lower frequency (42%) observed in our series of FCLs may be partly attributed to the fact that only the major breakpoint region probe was used to assess rearrangement status and this probe detects approximately 60% of t(18q21) translocations. Other investigators also included the minor cluster region probe as part of their analysis.

In our study, we observed alterations of the c-MYC locus in 50% of T-lymphoblastic lymphomas, 25% of high-grade B-cell lymphomas, 14% of DLBC lymphomas and in the single Burkitt’s...
lymphoma case included in our study. These subtypes comprise tumours that behave in a clinically aggressive manner. Previous reports show involvement of the t(8;14) translocation in almost all cases of Burkitt’s lymphoma as well as in a subset of large-cell lymphomas. The t(8;14) invariably results in deregulation of the c-MYC oncogene, with subsequent overexpression of the gene product. The MYC product has been shown to be a member of the leucine zipper family of DNA-binding proteins and has been implicated as a potent regulator of cellular proliferation (Stewart et al, 1984). In this study, we report unusual occurrences of c-MYC rearrangements in two FCLs. Other investigators have reported rare or no cases of t(8;24) in their series of FCLs (Donti et al, 1988; Juneja et al, 1990; Yano et al, 1992). Interestingly, we found a case of FCL (showing areas of diffuse histology) positive for both c-MYC and BCL-2 rearrangements. The patient’s tumour was clinically aggressive and the patient died 36 months after diagnosis. It would be interesting to know whether the acquisition of the c-MYC rearrangement influenced the tumour’s progression to a more aggressive subtype. However, we have no further histology reports in medical records to support this hypothesis.

Also, we report a FCL (grade II) with involvement of t(8;24). The patient’s previous biopsy showed a grade I FCL which recurred and progressed to a grade II FCL. The patient died 30 months later, which again reinforces the idea that the acquisition of this genetic anomaly may lead to the development of tumours with poor prognostic implications. Isolated case reports (Gauwerky et al, 1988; Lee et al, 1989) have appeared in the literature implicating c-MYC in the histological progression of some low-grade follicular lymphomas. Studies in transgenic mice provide an animal model for tumour progression in t(14;18) lymphoma, showing that evolution into a more aggressive lymphoma is accompanied by c-MYC rearrangements in half of the cases (McDonnell et al, 1991).

Recently, much interest has centred on a newly described gene, BCL-6, because of its involvement in a large subset of clinically important DLBC lymphomas. Our data showed rearrangement of BCL-6 to be the most frequent genetic abnormality detectable in our series of DLBC lymphomas (31%; 9 out of 29). This incidence is similar to previous reports – 29% of diffuse aggressive lymphomas reported by Otsuki et al (1995), 36% reported by LoCoco et al (1994) and 37% by Bastard et al (1994).

We detected 4% (1 out of 25) of FCLs to be positive for this rearrangement; Bastard et al (1994) reported this specific alternation in 13% (11 out of 84) and LoCoco et al (1994) in 6% (2 out of 31) of their respective series of follicular lymphoma cases.

The tumours with BCL-6 rearrangements were all of B-cell origin, and 50% had co-existing gene rearrangements. These involved the BCL-2 gene in three cases, the BCL-1 gene in one case and c-MYC in the remaining two. Two DLBC lymphomas had coexisting BCL-6 and BCL-2 rearrangements. This contrasts with the findings of LoCoco et al (1994) who report the absence of BCL-2 rearrangement in their series of BCL-6-rearrangement-positive DLBC (16 out of 45) lymphomas, hence suggesting that BCL-6 may define an independent pathway from BCL-2 in lymphomagenesis. However, our findings are substantiated by others, who showed coexisting BCL-2 and BCL-6 rearrangements in transformed lymphomas (17%; 9 out of 52) (Otsuki et al, 1995) as well as in de novo DLBC lymphomas (21%; 8 out of 39) (Bastard et al, 1994), thereby strongly suggesting that these two events are unlikely to be exclusive of one another.

We show coexisting BCL-2 and BCL-6 rearrangements in a DLBC lymphoma that had transformed from a low-grade FCL. The original biopsy specimen (FCL, grade I) also demonstrated a BCL-6 rearrangement. We also report a DLBC lymphoma demonstrating both BCL-1 and BCL-6 rearrangements that had an antecedent history of a low-grade lymphoma. The BCL-6 rearrangement status of the original biopsy is not known. The question of BCL-6 participating in the transformation process of some lymphoid malignancies remains unanswered; this needs to be resolved by accumulating and analysing more cases accompanied by clear medical history records. However, another consideration is the fact that the partner chromosomes of BCL-6 are numerous and may represent the sites of known, as well as of yet uncharacterized, gene loci perhaps harbouring unidentified genes, which may influence the progress of the process.

A DLBC lymphoma demonstrating both BCL-6 and c-MYC rearrangements was clinically aggressive, resulting in the patient’s death 7 months after diagnosis. This might suggest that this combination of genetic events precipitates a tumour of poor prognostic implications.

In conclusion, our work has illustrated that associations exist between specific genomic alterations and defined subtypes of NHL. In addition, we report the interesting finding of coexisting rearrangements in a large percentage of the BCL-6-rearrangement-positive lymphoma cases. The identification of these molecular markers can be exploited in the diagnostic field, as well as aiding our understanding of the molecular pathogenesis of the diverse histological subtypes of NHL. Such markers may, in the future, be used to stratify lymphoma patients into different subgroups that share common genetic profiles. This novel classification scheme may then allow more accurate prediction of tumour biologies.

**ABBREVIATIONS**

NHL, Non-Hodgkin’s lymphoma; DLBC, diffuse large B cell lymphoma; FCL, follicle centre lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; SNCCL, small non-cleaved cell lymphoma; REAL, Revised European–American Lymphoma; WF, working formulation; FISH, fluorescence in situ hybridization; MTC, major translocation cluster

**ACKNOWLEDGEMENTS**

The authors would like to thank Dr Amanda McCann and Dr Liz Moore for their advice in this paper. Also I am grateful to Dr Anna Migliazza and Dr Shinako Iida for reviewing this manuscript.

I would like to extend special thanks to Giorgio Cattoretti for his help in reviewing some histology slides. This work was in part supported by grants from the Irish Cancer Society as well as the Cancer Research Board.

**REFERENCES**

Arnold A, Kim HG, Gaz RD, Eddy RL, Fukushima Y, Byers MG, Shows TB and Kronenberg HM (1989) Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83: 2034–2040

Athan E, Fotil DR and Knowles DM (1991) BCL-1 rearrangement, frequency and clinical significance among B-cell chronic lymphocytic leukaemias and non-Hodgkin’s lymphomas. Am J Pathol 138: 591–599
Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride DW, Epstein AL and Korsmeyer SJ (1985) Cloning the chromosomal breakpoint t(14;18) in human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41: 889–906

Baron BW, Nucoform G, McCabe N, Espinosa R, Lebeau MM and McKeanin T (1993) Identification of the gene associated with the recurring chromosomal translocation t(14;18)(q32;q21) in B-cell lymphomas. Proc Natl Acad Sci USA 90: 5262–5266

Bastard C, Deweindt C, Kerkcaraet JP, Lenonand A, Ross A, Pezzella F, Fruchart C, Duvia C, Montoando H and Tilly H (1994) LAZ3 rearrangement in non-Hodgkin's lymphoma. Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 83: 2423–2427

Berard C and Dornann RP (1974) Histopathology of malignant lymphomas. Clin Haematol 3: 39–44

Clark HM, Jones DB and Wright DH (1992) Cyto genetic and molecular studies of t(14;18) and t(14;19) in nodal and extranodal B-cell lymphoma. J Pathol 166: 129–137

Cleary ML and Sklar J (1985) Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 90: 5262–5266

Cotter FE (1990) The role of the BCL-2 gene in lymphoma. Br J Haematol 75: 449–453

Croce CM and Nowell PC (1985) Molecular basis of human B-cell neoplasia. Blood 65: 1–7

Dalla-Favera RM, Bregni M, Erickson J, Patterson D, Gallo RC and Croce CM (1982) Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 79: 7824–7827

Deboer CJ, Loysoy S, Kluin PM, Kluin-Nelemans HC, Schuuring E and Vakriejen JHM (1993) Multiple breakpoints within the BCL1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res 53: 4148–4153

Dejong D, Voetjik BHMM, Van Ommen GLB, Kluin-Nelemans JC, Beverstos GC and Kluin PM (1989) Translocation t(14;18) in B-cell lymphomas as a cause for defective immunoglobulin production. J Exp Med 169: 613–624

Doni E, Falina B, Pelizzi PG, Doni GV, Rosetti A, Martelli M, Grignani F (1988) Immunologocal and molecular studies in a case of follicular lymphoma with an extra chromosome 12 and t(2;8) translocation. Leukemia 2: 41–44

Gauwerk CY, Haluska FG, Tsujimoto Y, Nowell PC and Croce CM (1988) Evolution of B-cell malignancy: pre-B-cell leukaemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL-2 gene. Proc Natl Acad Sci USA 85: 8548–8552

Gareard-Marchant R, Hamlin I, Lennert K, Rilke F, Stansfeld AG, Vanunick IAM (1974) Classification of non-Hodgkin's lymphoma. Lancet 2: 406–411

Granger WB, Seto M, Boutain B, Goldman P and Korsmeyer SJ (1987) Expression of BCL-2 and BCL-2/fg transcripts in normal and neoplastic cells. J Clin Invest 80: 1512–1516

Haris NL, Jaff ES, Stein H, Banks PM, Chan JK, Cleary M, Delson G, Wolfers CD, Falini B, Gatter KC, Grogan TM, Isaacson PG, Grignani DM, Mason DY, Muller-Hermelink H, Pileri M, Raffkiger E and Warkske RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 84: 1361–1387

Hockenbery JR, Nunez G, Milliann C, Schreiber RD and Korsmeyer SJ (1990) BCL-2 is an inner mitochondial membrane that blocks programmed cell death. Nature 348: 334–336

Huntz T and Pines J (1994) Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 79: 573–578

Iida S, Rao P, Nallasivam P, Hikishoou H, Butler M, Louise D, Dyomin V, Oohno H, Chaganti RSK and Dallavera-Favera R (1996) The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88: 4100–4117

Jineja S, Luukis K, Cooper TJ, Szlezaj G, Parkin JD, Ironsides, Kerkcaraet JP, Deweindt C, Tilly H, Quiet S, Locceg G and Bastard C (1993) LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet 6: 66–70

Koduru PRK, Filipa DA and Richardson ME (1987) Cyto genetic and histologic correlations in malignant lymphoma. Blood 60: 97–102

Komatsu H, Iida S, Yamamoto K, Mikumi C, Nitta M, Takahashi T, Ueda R and Seto M (1994) A variable recurrent translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 84: 1226–1231

Lambrecht AC, Deruitere PE, Dorsors LCJ and Van't Verve MB (1992) Detection of residual disease in transplantation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: a comparison with conventional staging methods. Leukaemia 6: 29–34